Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity

C. J. Betti, M. J. Villalobos, Q. Jiang, E. Cline, M. O. Diaz, G. Loredo, Andrew T M Vaughan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3kbp tract, the breakpoint cluster region (BCR). Using an in vitro assay, apoptotic activators, including radiation and anti-CD95 antibody, trigger site-specific cleavage adjacent to exon 12 within the MLL BCR and promote translocation of the MLL gene in cells that can survive. To explore the mechanism of cleavage and rearrangement in more detail, the entire MLL BCR was placed into the pREP4 episomal vector and transfected into human lymphoblastoid TK6 cells. Episomes containing either the MLL BCR, or deletion constructs of 367bp or larger, were cleaved at the same position as genomic MLL after exposure to apoptotic stimuli. Further analysis of sequence motifs surrounding the cleaved region of MLL showed the presence of both a predicted nuclear matrix attachment sequence and a potential strong binding site for topoisomerase II, flanking the site of cleavage. Inactivation of topoisomerase II by the catalytic inhibitor merbarone did not inhibit MLL cleavage, suggesting that the initial cleavage step for MLL rearrangement is not mediated by topoisomerase II.

Original languageEnglish (US)
Pages (from-to)2289-2295
Number of pages7
JournalLeukemia
Volume19
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Topoisomerase II Inhibitors
Type II DNA Topoisomerase
merbarone
Apoptosis
Nuclear Matrix
Genes
Sequence Analysis
Anti-Idiotypic Antibodies
Exons
Leukemia
Plasmids
Binding Sites
Radiation
In Vitro Techniques

Keywords

  • Apoptosis
  • High molecular weight fragmentation
  • Merbarone
  • MLL (mixed lineage leukemia)
  • tATML (therapy related AML)
  • Topoisomerase II

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Betti, C. J., Villalobos, M. J., Jiang, Q., Cline, E., Diaz, M. O., Loredo, G., & Vaughan, A. T. M. (2005). Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia, 19(12), 2289-2295. https://doi.org/10.1038/sj.leu.2403966

Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. / Betti, C. J.; Villalobos, M. J.; Jiang, Q.; Cline, E.; Diaz, M. O.; Loredo, G.; Vaughan, Andrew T M.

In: Leukemia, Vol. 19, No. 12, 12.2005, p. 2289-2295.

Research output: Contribution to journalArticle

Betti, CJ, Villalobos, MJ, Jiang, Q, Cline, E, Diaz, MO, Loredo, G & Vaughan, ATM 2005, 'Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity', Leukemia, vol. 19, no. 12, pp. 2289-2295. https://doi.org/10.1038/sj.leu.2403966
Betti CJ, Villalobos MJ, Jiang Q, Cline E, Diaz MO, Loredo G et al. Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia. 2005 Dec;19(12):2289-2295. https://doi.org/10.1038/sj.leu.2403966
Betti, C. J. ; Villalobos, M. J. ; Jiang, Q. ; Cline, E. ; Diaz, M. O. ; Loredo, G. ; Vaughan, Andrew T M. / Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. In: Leukemia. 2005 ; Vol. 19, No. 12. pp. 2289-2295.
@article{44b908e38a654e1da04810c2505412da,
title = "Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity",
abstract = "Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3kbp tract, the breakpoint cluster region (BCR). Using an in vitro assay, apoptotic activators, including radiation and anti-CD95 antibody, trigger site-specific cleavage adjacent to exon 12 within the MLL BCR and promote translocation of the MLL gene in cells that can survive. To explore the mechanism of cleavage and rearrangement in more detail, the entire MLL BCR was placed into the pREP4 episomal vector and transfected into human lymphoblastoid TK6 cells. Episomes containing either the MLL BCR, or deletion constructs of 367bp or larger, were cleaved at the same position as genomic MLL after exposure to apoptotic stimuli. Further analysis of sequence motifs surrounding the cleaved region of MLL showed the presence of both a predicted nuclear matrix attachment sequence and a potential strong binding site for topoisomerase II, flanking the site of cleavage. Inactivation of topoisomerase II by the catalytic inhibitor merbarone did not inhibit MLL cleavage, suggesting that the initial cleavage step for MLL rearrangement is not mediated by topoisomerase II.",
keywords = "Apoptosis, High molecular weight fragmentation, Merbarone, MLL (mixed lineage leukemia), tATML (therapy related AML), Topoisomerase II",
author = "Betti, {C. J.} and Villalobos, {M. J.} and Q. Jiang and E. Cline and Diaz, {M. O.} and G. Loredo and Vaughan, {Andrew T M}",
year = "2005",
month = "12",
doi = "10.1038/sj.leu.2403966",
language = "English (US)",
volume = "19",
pages = "2289--2295",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity

AU - Betti, C. J.

AU - Villalobos, M. J.

AU - Jiang, Q.

AU - Cline, E.

AU - Diaz, M. O.

AU - Loredo, G.

AU - Vaughan, Andrew T M

PY - 2005/12

Y1 - 2005/12

N2 - Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3kbp tract, the breakpoint cluster region (BCR). Using an in vitro assay, apoptotic activators, including radiation and anti-CD95 antibody, trigger site-specific cleavage adjacent to exon 12 within the MLL BCR and promote translocation of the MLL gene in cells that can survive. To explore the mechanism of cleavage and rearrangement in more detail, the entire MLL BCR was placed into the pREP4 episomal vector and transfected into human lymphoblastoid TK6 cells. Episomes containing either the MLL BCR, or deletion constructs of 367bp or larger, were cleaved at the same position as genomic MLL after exposure to apoptotic stimuli. Further analysis of sequence motifs surrounding the cleaved region of MLL showed the presence of both a predicted nuclear matrix attachment sequence and a potential strong binding site for topoisomerase II, flanking the site of cleavage. Inactivation of topoisomerase II by the catalytic inhibitor merbarone did not inhibit MLL cleavage, suggesting that the initial cleavage step for MLL rearrangement is not mediated by topoisomerase II.

AB - Exposure to topoisomerase II inhibitors is linked to the generation of leukemia involving translocations of the MLL gene, normally restricted to an 8.3kbp tract, the breakpoint cluster region (BCR). Using an in vitro assay, apoptotic activators, including radiation and anti-CD95 antibody, trigger site-specific cleavage adjacent to exon 12 within the MLL BCR and promote translocation of the MLL gene in cells that can survive. To explore the mechanism of cleavage and rearrangement in more detail, the entire MLL BCR was placed into the pREP4 episomal vector and transfected into human lymphoblastoid TK6 cells. Episomes containing either the MLL BCR, or deletion constructs of 367bp or larger, were cleaved at the same position as genomic MLL after exposure to apoptotic stimuli. Further analysis of sequence motifs surrounding the cleaved region of MLL showed the presence of both a predicted nuclear matrix attachment sequence and a potential strong binding site for topoisomerase II, flanking the site of cleavage. Inactivation of topoisomerase II by the catalytic inhibitor merbarone did not inhibit MLL cleavage, suggesting that the initial cleavage step for MLL rearrangement is not mediated by topoisomerase II.

KW - Apoptosis

KW - High molecular weight fragmentation

KW - Merbarone

KW - MLL (mixed lineage leukemia)

KW - tATML (therapy related AML)

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=28544437234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544437234&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403966

DO - 10.1038/sj.leu.2403966

M3 - Article

VL - 19

SP - 2289

EP - 2295

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -